CSIMarket
 


Atara Biotherapeutics Inc   (ATRA)
Other Ticker:  
 
 

ATRA's Capital Expenditures Growth by Quarter and Year

Atara Biotherapeutics Inc 's Capital Expenditures results by quarter and year




ATRA Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 0.04 2.47 0.50
III Quarter September 0.28 0.13 3.86 2.08
II Quarter June 0.50 1.42 2.06 1.33
I Quarter March 0.40 2.61 2.20 2.71
FY   1.18 4.20 10.59 6.62



ATRA Capital Expenditures third quarter 2023 Y/Y Growth Comment
Atara Biotherapeutics Inc reported Capital Expenditures surge of 116.15% year on year in the third quarter 2023, to $ 0.28 millions, this is lower than Atara Biotherapeutics Inc 's recent average Capital Expenditures surge of 782.17%.

Looking into third quarter 2023 results within Biotechnology & Pharmaceuticals industry 25 other companies have achieved higher Capital Expenditures growth. While Atara Biotherapeutics Inc ' s Capital Expenditures doubling of 116.15% ranks overall at the positon no. 450 in the third quarter 2023.




ATRA Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - -98.38 % 394 % -66.44 %
III Quarter September 116.15 % -96.63 % 85.58 % 181.08 %
II Quarter June -64.79 % -31.07 % 54.89 % 66.25 %
I Quarter March -84.67 % 18.64 % -18.82 % -35.01 %
FY   - -60.34 % 59.97 % -8.06 %

Financial Statements
Atara Biotherapeutics Inc 's third quarter 2023 Capital Expenditures $ 0.28 millions ATRA's Income Statement
Atara Biotherapeutics Inc 's third quarter 2022 Capital Expenditures $ 0.13 millions Quarterly ATRA's Income Statement
New: More ATRA's historic Capital Expenditures Growth >>


ATRA Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - -69.23 % -36.01 % -75.96 %
III Quarter September -43.8 % -90.85 % 87.38 % 56.39 %
II Quarter June 25 % -45.59 % -6.36 % -50.92 %
I Quarter March 900 % 5.67 % 340 % 81.88 %
FY (Year on Year)   - -60.34 % 59.97 % -8.06 %




Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #26
Healthcare Sector #109
Overall #450

Capital Expenditures Y/Y Growth Statistics
High Average Low
17720 % 782.17 % -98.5 %
(Mar 31 2016)   (Dec 31 2022)
Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #26
Healthcare Sector #109
Overall #450
Capital Expenditures Y/Y Growth Statistics
High Average Low
17720 % 782.17 % -98.5 %
(Mar 31 2016)   (Dec 31 2022)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Atara Biotherapeutics Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
1835.71 % 99.05 % -100 %
(Dec 31 2015)  


ATRA's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2023 Atara Biotherapeutics Inc disclosed fall in Capital Expenditures from the second quarter by -43.8% to $ 0.28 millions, from $ 0.50 millions released in the previous reporting period.

But that's not big concern, as Capital Expenditures frequently tend to slow in this quarter Daniel  Surname, a business veteran told.

Within Biotechnology & Pharmaceuticals industry 5 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Atara Biotherapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 525.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #6
Healthcare Sector #48
Overall #525
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #6
Healthcare Sector #48
Overall #525
Capital Expenditures Q/Q Growth Statistics
High Average Low
1835.71 % 99.05 % -100 %
(Dec 31 2015)  


ATRA's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2023 Atara Biotherapeutics Inc disclosed fall in Capital Expenditures from the second quarter by -43.8% to $ 0.28 millions, from $ 0.50 millions released a quarter before.

As we look into recent slump at the III. Quarter, we must assume, that frequently III. Quarter Capital Expenditures occur sluggish then in the quarter before

Within Biotechnology & Pharmaceuticals industry 5 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Atara Biotherapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 525.


Atara Biotherapeutics Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 1.22 $ 1.07 $ 1.99 $ 4.19 $ 6.62
Y / Y Capital Expenditures Growth (TTM) -81.64 % -89.69 % -81.92 % -60.37 % -23.15 %
Year on Year Capital Expenditures Growth Overall Ranking # 1596 # 191 # 464 # 0 # 1679
Seqeuential Capital Expenditures Change (TTM) 13.96 % -46.3 % -52.61 % -36.68 % -35.99 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 2032 # 827 # 873 # 0 # 2188




Cumulative Capital Expenditures growth Comment
Atara Biotherapeutics Inc showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Jun 30 2023. If the fiscal year would end in Sep 30 2023, Atara Biotherapeutics Inc 's annual Capital Expenditures drop would be -81.64% year on year to $1 millions.

In the Healthcare sector 232 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 191 to 1596.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
818.93 %
93.03 %
-89.69 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 40
Healthcare Sector # 233
Overall # 1596

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
818.93 %
93.7 %
-89.69 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 40
Sector # 285
S&P 500 # 2032
Cumulative Capital Expenditures growth Comment
Atara Biotherapeutics Inc showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Jun 30 2023. If the fiscal year would end in Sep 30 2023, Atara Biotherapeutics Inc 's annual Capital Expenditures drop would be -81.64% year on year to $1 millions.

In the Healthcare sector 232 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 191 to 1596.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
818.93 %
93.03 %
-89.69 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 40
Healthcare Sector # 233
Overall # 1596

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
818.93 %
93.7 %
-89.69 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 40
Sector # 285
S&P 500 # 2032




Other Capital Expenditures Growth
Biotechnology & Pharmaceuticals Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
ATRA's Capital Expenditures Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for ATRA's Competitors
Capital Expenditures Growth for Atara Biotherapeutics Inc 's Suppliers
Capital Expenditures Growth for ATRA's Customers

You may also want to know
ATRA's Annual Growth Rates ATRA's Profitability Ratios ATRA's Asset Turnover Ratio ATRA's Dividend Growth
ATRA's Roe ATRA's Valuation Ratios ATRA's Financial Strength Ratios ATRA's Dividend Payout Ratio
ATRA's Roa ATRA's Inventory Turnover Ratio ATRA's Growth Rates ATRA's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2023
Hims and Hers Health Inc 201.89%$ 201.887 millions
Cerevel Therapeutics Holdings Inc 200.00%$ 200.000 millions
Halozyme Therapeutics Inc 192.06%$ 192.063 millions
Rhythm Pharmaceuticals inc 187.37%$ 187.368 millions
Caribou Biosciences Inc 187.30%$ 187.304 millions
Clearside Biomedical Inc 187.10%$ 187.097 millions
Voyager Therapeutics Inc 181.29%$ 181.295 millions
Seagen Inc 175.70%$ 175.700 millions
Immunome Inc174.45%$ 174.453 millions
Armata Pharmaceuticals Inc 171.41%$ 171.406 millions
Iovance Biotherapeutics Inc 157.89%$ 157.895 millions
Escalon Medical Corp 156.16%$ 156.157 millions
Perspective Therapeutics Inc 152.22%$ 152.222 millions
Cognition Therapeutics inc 152.17%$ 152.174 millions
Maravai Lifesciences Holdings Inc 144.73%$ 144.735 millions
Lantheus Holdings Inc 140.08%$ 140.082 millions
Teva Pharmaceutical Industries Limited136.07%$ 136.066 millions
Humacyte Inc 133.65%$ 133.649 millions
Intra cellular Therapies Inc 129.06%$ 129.060 millions
Lemaitre Vascular Inc 128.91%$ 128.913 millions
Orthopediatrics Corp127.64%$ 127.640 millions
Immunogen inc 124.92%$ 124.917 millions
Aditxt Inc 123.67%$ 123.667 millions
Omega Therapeutics Inc 120.73%$ 120.732 millions
Fusion Pharmaceuticals Inc 113.06%$ 113.063 millions
Surmodics Inc112.94%$ 112.937 millions
Atara Biotherapeutics Inc 112.88%$ 112.879 millions
Zimmer Biomet Holdings Inc 106.36%$ 106.356 millions
Pieris Pharmaceuticals Inc 102.94%$ 102.941 millions
Thermogenesis Holdings Inc 102.25%$ 102.247 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com